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Time to treatment with intravenous alteplase and
outcome in stroke: an updated pooled analysis of ECASS,
ATLANTIS, NINDS, and EPITHET trials
Why is this study of clinical importance?
Stroke outcomes improve with early administration
of intravenous recombinant tissue plasminogen activator
(rt-PA). Analysis of combined data from individual patients
from different studies has suggested potential benefit
beyond 3 hours from stroke onset. 
This study is an updated pooled analysis that aimed
to assess the effect of time to treatment with the intravenous
rt-PA alteplase on therapeutic benefit and clinical risk. The
hypothesis of this updated pool is that the benefit of rt-PA
would be smaller and the risk greater in patients who were
treated at later time points within the 6-h our window after
stroke onset. As intravenous rt-PA alteplase is the main
treatment in acute stroke, it is important to know the clinical
benefits and harms associated with the extension of time
window for alteplase.
What are the trials included in this study?
Eight trials are analyzed in this study which
represents the major randomized placebo controlled trials of
r-PA (alteplase) for acute stroke. These trials are the two
NINDS trials (parts 1 and 2), the first two ECASS trials, two
Alteplase Thrombolysis for Acute Noninterventional
Therapy in Ischaemic Stroke (ATLANTIS) trials and
Echoplanar Imaging Thrombolytic Evaluation Trial
(EPITHET).
The time allowed from stroke onset to start of
treatment (OTT) varied among trials. In the NINDS studies,
the protocols dictated that treatment start within 3 hours of
onset of symptoms, and within 90 min for half the patients.
In ECASS and ECASS II, patients were enrolled 0-360 min
from symptom onset. ECASS III included patients between
180 min and 270 min from stroke onset. Patients in
ATLANTIS A were enrolled from 0 min to 360 min.
ATLANTIS B initially recruited patients timeframe was
restricted to 180-300 min from symptom onset. EPITHET
included patients from 180-360 min only.
What was the intervention?
In NINDS, ATLANTIS, ECASS II, ECASS III, and
EPITHET, patients in the alteplase group were assigned to
receive a total intravenous dose of 0·9 mg/kg bodyweight
(90 mg maximum) whereas in ECASS I the total dose was
1·1 mg/kg (100 mg maximum).All studies gave 10% of the
dose as a bolus during the first minute. The remainder was
infused over 1 hour. Patients allocated to control groups
received matching infusions of placebo. All trials allowed
inclusion of patients who had taken antiplatelet agents
before their stroke, but precluded the use of oral or
intravenous anticoagulants or antiplatelet agents for the first
24 hours after treatment. 
What was the outcome?
Investigators in all studies measured NIHSS score,
modified Rankin Scale, and Barthel Index up to 3 months
after stroke onset, calculated mortality, carefully determined
the occurrence of haemorrhage with CT, and relied on
clinical scales for their primary outcome measures.
This pooled analysis focused on the 3-month
favourable outcome defined in two ways: by modified
Rankin Scale (0-1) alone; and by a composite measure
consisting of three neurological function scores of modified
Rankin Scale (0-1), Barthel Index (95-100), and NIHSS (0-
1). For all three measures the dichotomies were chosen to
represent minimal or no post stroke deficit (favourable, not
favourable). Of particular interest was the extent to which
the odds of a favourable outcome altered as OTT increased. 
Treatment was started within 360 min of stroke onset
in 3670 patients randomly allocated to alteplase (n=1850) or
to placebo (n=1820). Odds of a favorable 3-month outcome
increased as OTT decreased (p=0·0269) and no benefit t of
alteplase treatment was seen after around 270 min. 
Around one in three patients treated with alteplase
within 3 hours of symptom onset, and one in six treated
within 4.5 hours, achieves significant benefit. This analysis
identified that approximately five patients need to be treated
0-90 min, nine patients 91-180 min, or 15 patients 181-270
min after symptom onset for one of them to have an
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excellent outcome attributable to treatment.
What were the conclusions?
This updated pooled analysis shows that treatment
with thrombolysis until 4.5 hours from stroke onset
enhances the chance of favourable outcome. Serious
haemorrhage rates are independent of OTT, but mortality
increases with OTT longer than 4.5 hours. However, across
the time window studied, this analysis showed that the
greatest benefit t comes from earlier treatment, since net
benefit is diminishing with time and beyond 4.5 hours, risk
might outweigh benefit
How does this impact us?
This pooled analysis reemphasises on the
importance of time window in the clinical management of
acute ischaemic stroke with alteplase. Although clinical
benefit of alteplase is seen up to 4.5 hours in carefully
selected patients, to increase benefit to a maximum, every
effort should be taken to shorten delay in initiation of
treatment. Given the great expense and disability of stroke,
we need to upgrade the infrastructure that can support such
treatment in more centers throughout Pakistan. In addition,
perhaps looking into cheaper thrombolytic agents, drug
delivery within transit, telestroke are other viable options
for stroke patients in far flung areas in Pakistan. 
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